Dr Stephen Hiscox

2024

• Chakrabarty, A. , Hiscox, S. and Ranganathan, P. 2024. Resistance to endocrine therapies in cancer, volume II [Editorial]. Frontiers in Endocrinology 15 1414392. (10.3389/fendo.2024.1414392)

2021

• Cai, S. et al. 2021. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. International Journal of Oncology 58 (6) 34. (10.3892/ijo.2021.5214)

2020

• Rees, M. et al. 2020. PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer. Oncotarget 11 (51), pp.4722-4734. (10.18632/oncotarget.27846)
• Kandil, S. B. et al. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25 (15) 3488. (10.3390/molecules25153488)
• Ranganathan, P. et al., 2020. Editorial: Resistance to endocrine therapies in cancer. Frontiers in Endocrinology 11 196. (10.3389/fendo.2020.00196)

2018

• Davison, Z. et al., 2018. Co-administration of fish oil with signal transduction inhibitors has anti-migration effects in breast cancer cell lines, in vitro. The Open Biochemistry Journal 12 (1), pp.130-148. (10.2174/1874091X01812010130)
• Kandil, S. et al. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91 (1), pp.314-321. (10.1111/cbdd.13083)

2016

• Wymant, J. et al. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7 (15), pp.2388-2407. (10.7150/jca.15055)
• Jones, S. et al. 2016. Targeting metastasis and cancer stem-like cells in triple negative breast cancer through inhibition of focal adhesion kinase [Poster Abstract]. Presented at: AACR 107th Annual Meeting 2016 New Orleans, LA, USA 16-20 April 2016. Vol. 76.Vol. S14. , pp.4125. (10.1158/1538-7445.am2016-4125)
• Bellerby, R. et al. 2016. Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology 6 145. (10.3389/fonc.2016.00145)
• Gangadhara, S. et al., 2016. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer 16 (1) 345. (10.1186/s12885-016-2377-z)

2015

• Elseginy, S. A. et al. 2015. Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. Bioorganic and Medicinal Chemistry Letters 25 (4), pp.758-762. (10.1016/j.bmcl.2014.12.095)
• Wiggins, H. L. et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93 (3), pp.332-342. (10.1016/j.bcp.2014.12.014)

2013

• Lazaro, G. et al. 2013. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer 20 (5), pp.691-704. (10.1530/ERC-13-0019)
• Eccles, S. A. et al., 2013. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research 15 (5), pp.R92. (10.1186/bcr3493)
• Hogstrand, C. et al. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455 (2), pp.229-237. (10.1042/BJ20130483)

2012

• Gangadhara, S. et al. 2012. Pro-metastatic tumor-stroma interactions in breast cancer. Future Oncology 8 (11), pp.1427-1442. (10.2217/fon.12.134.)
• Hiscox, S. E. et al. 2012. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 12 458. (10.1186/1471-2407-12-458)
• Taylor, K. M. et al. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5 (210) ra11. (10.1126/scisignal.2002585)

2011

• Hiscox, S. E. , Barrett-Lee, P. and Nicholson, R. I. 2011. Therapeutic targeting of tumor–stroma interactions. Expert Opinion on Therapeutic Targets 15 (5), pp.609-621. (10.1517/14728222.2011.561201)
• Hiscox, S. E. et al. 2011. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Research and Treatment 125 (3), pp.659-669. (10.1007/s10549-010-0857-4)
• Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5 (2), pp.67-77. (10.1515/HMBCI.2011.009)
• Wadhawan, A. et al. 2011. Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention. Cancer Treatment Reviews 37 (3), pp.234-241. (10.1016/j.ctrv.2010.08.003)
• Davies, E. and Hiscox, S. E. 2011. New therapeutic approaches in breast cancer. Maturitas 68 (2), pp.121-128. (10.1016/j.maturitas.2010.10.012)
• Hayes, E. R. , Nicholson, R. I. and Hiscox, S. E. 2011. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Frontiers in Bioscience 16 (1), pp.838-848. (10.2741/3723)

2010

• Hiscox, S. E. et al. 2010. Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss. European Journal of Cancer 46 (12), pp.2187-2195. (10.1016/j.ejca.2010.04.012)
• Weaver, B. P. et al., 2010. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. PLoS ONE 5 (10) e13158. (10.1371/journal.pone.0013158)

2009

• Hiscox, S. E. et al. 2009. Inhibition of Focal Adhesion Kinase Suppresses Adverse Features of Endocrine-Resistant Breast Cancer Cells and Improves Endocrine Response in ER plus , Endocrine-Sensitive Cells [Abstract]. Cancer Research 69 (24:S1), pp.3130. (10.1158/0008-5472.SABCS-09-3130)
• Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8 (16), pp.1550-1558. (10.4161/cbt.8.16.8954)
• Baruah, B. P. et al. 2009. CD44-Activated HER-2 Signalling in Tamoxifen Resistant Breast Cancer Cells Promotes a Migratory Phenotype. Cancer Research 69 (24), pp.811S-811S.
• Baruah, B. P. et al. 2009. Overexpression of CD44 in acquired endocrine resistant breast cancer modulates erbB activity and promotes an invasive phenotype. Cancer Research 69 (2), pp.811S-811S.
• Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.63-84. (10.1007/978-1-4020-8526-0_4)
• Hiscox, S. E. et al. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer. , pp.139-160. (10.1007/978-1-4020-8526-0_8)
• Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1)
• Hiscox, S. E. , Davies, E. and Barrett-Lee, P. 2009. Aromatase inhibitors in breast cancer. Maturitas 63 (4), pp.275-279. (10.1016/j.maturitas.2009.05.008)
• Hiscox, S. E. et al. 2009. Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype [Abstract]. Cancer Research 69 (2), pp.213S-213S. (10.1158/0008-5472.SABCS-3028)
• Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115 (1), pp.57-67. (10.1007/s10549-008-0058-6)
• Hiscox, S. E. and Nicholson, R. I. 2009. Resistance to hormone therapy in breast cancer. Advances in Breast Cancer 6 (3), pp.2-6.
• Wadhawan, A. et al. 2009. Src-Dependent Changes in Beta-Catenin Activity Promote a Migratory Phenotype in Endocrine-Resistant Breast Cancer Cells. Cancer Research 69 (24), pp.813S.

2008

• Taylor, K. M. et al. 2008. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology 149 (10), pp.4912-4920. (10.1210/en.2008-0351)
• Borley, A. C. et al. 2008. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Research 10 (6) R103. (10.1186/bcr2206)
• Hiscox, S. E. et al. 2008. Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1 [Abstract]. Breast Cancer Research 10 (S2) P34. (10.1186/bcr1918)
• Hiscox, S. E. and Nicholson, R. I. 2008. Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets 12 (6), pp.757-767. (10.1517/14728220802133204)
• Morgan, L. D. , Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8 (4), pp.273-278. (10.2174/187153008786848295)
• Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare. , pp.123-136.
• Taylor, K. M. et al. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10 (s2) P42. (10.1186/bcr1926)

2007

• Borley, A. C. et al., 2007. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Research and Treatment 106 (Supp 1), pp.S7-S8.
• Hiscox, S. E. et al. 2007. Combination treatment with AZD0530 and tamoxifen prevents acquired antiestrogen resistance in breast cancer cells [Abstract]. Molecular Cancer Therapeutics 6 (Suppl), pp.3411S.
• Hiscox, S. E. et al. 2007. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical & Experimental Metastasis 24 (3), pp.157-167. (10.1007/s10585-007-9065-y)
• Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9 (4) R50. (10.1186/bcr1754)
• Khirwadkar, Y. et al. 2007. HGF/SF promotes an aggressive phenotype in c-Met-overexpressing fulvestrant-resistant MCF-7 cells - Evidence for MMP-9 and PI3k involvement [Abstract]. Annals of Oncology 18 (S4) P611. (10.1093/annonc/mdm166)
• Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8 (3), pp.241-253. (10.1007/s11154-007-9033-5)

2006

• Gee, J. M. W. et al. 2006. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer 13 (S1), pp.S77-S88. (10.1677/erc.1.01274)
• Hiscox, S. E. et al. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97 (3), pp.263-274. (10.1007/s10549-005-9120-9)
• Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118 (2), pp.290-301. (10.1002/ijc.21355)
• Hiscox, S. E. , Green, T. P. and Nicholson, R. I. 2006. Combination therapy using AZD0530 and tamoxifen prevents antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 100 (Supp 1), pp.S246-S246.
• Hiscox, S. E. et al. 2006. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocrine-Related Cancer 13 (4), pp.1085-1099. (10.1677/erc.1.01270)
• Hiscox, S. E. et al. 2006. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 13 , pp.S53-S59. (10.1677/erc.1.01297)

2005

• Nicholson, R. I. et al. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12 (S1), pp.S29-S36. (10.1677/erc.1.00991)
• Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93 (2-5), pp.257-262. (10.1016/j.jsbmb.2004.12.006)
• Hiscox, S. E. et al. 2005. Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion. Breast Cancer Research and Treatment 94 (Supp 1), pp.S161-S161.
• Taylor, K. M. et al. 2005. Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters. Breast Cancer Research and Treatment 94 (Supp 1), pp.S162-S162.

2004

• Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1), pp.346s-354s. (10.1158/1078-0432.CCR-031206)
• Hiscox, S. E. et al. 2004. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21 (3), pp.201-212. (10.1023/B:CLIN.0000037697.76011.1d)
• Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11 (4), pp.793-814. (10.1677/erc.1.00799)
• Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker. , pp.249-258.
• Taylor, K. M. , Hiscox, S. E. and Nicholson, R. 2004. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends in Endocrinology and Metabolism 15 (10), pp.461-463.

2003

• Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S171. (10.1023/A:1026252325164)

2002

• Hiscox, S. E. et al. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293 (2), pp.714-721. (10.1016/S0006-291X(02)00280-2)

2001

• Stephens, P. et al. 2001. Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts. Wound Repair and Regeneration 9 (1), pp.34-43. (10.1046/j.1524-475x.2001.00034.x)
• Hiscox, S. E. and Van Den Berg, C. W. 2001. Characterisation of cell activation through cyt2 and cyt1 tail of MCP. Molecular Immunology 38 (2-3), pp.96-97.
• Parr, C. et al., 2001. Inhibition of HGF/SF-induced cell-matrix adhesion, invasion, migration & paxillin phosphorylation, in prostate cancer by the HGF/SF antagonist, NK4. British Journal of Cancer 85 (Supp 1), pp.86-86. (10.1054/bjoc.2001.1918)

2000

• Hiscox, S. E. et al. 2000. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. British Journal of Cancer 59 (3), pp.245-254. (10.1023/A:1006348317841)
• Parr, C. et al. 2000. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. International Journal of Cancer 85 (4), pp.563-570. (10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D)
• Stead, P. et al., 2000. Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity. Biorganic and Medicinal Chemistry Letters 10 (7), pp.661-664.

1999

• Davies, G. et al., 1999. HGF/SF influences the interaction between APC, GSK3 beta and beta-catenin, its impact on cell adhesion and in vitro invasion in prostate cancer. British Journal of Cancer 80 (Supp 2), pp.36-36.
• Hiscox, S. E. and Jiang, W. G. 1999. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochemical and Biophysical Research Communications 261 (2), pp.406-411. (10.1006/bbrc.1999.1002)
• Hiscox, S. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. Journal of Cell Science 112 (18), pp.3081-3090.
• Hiscox, S. E. and Jiang, W. G. 1999. Hepatocyte growth factor scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Research 19 (1A), pp.509-517.
• Hiscox, S. E. , Mansel, R. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell adhesion and motility and associates with intercellular junctional proteins in cancer cells. British Journal of Cancer 81 (4), pp.579-579. (10.1038/sj.bjc.6690733)
• Jiang, W. G. et al. 1999. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology 29 (3), pp.209-248.
• Jiang, W. G. et al. 1999. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clinical Cancer Research 5 (11), pp.3695-3703.

1998

• Hiscox, S. E. , Davies, E. and Jiang, W. G. 1998. Up-regulation of the expression of hepatocyte growth factor activator (HGFA) in breast cancer. British Journal of Cancer 78 (2), pp.150-150. (10.1038/bjc.1998.457)
• Jiang, W. et al., 1998. The effects of n-6 polyunsaturated fatty acids on the expression of metastasis suppressors in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids Edinburgh, UK 20-24 July 1997. Published in: Riemersma, R. A. et al., The Fourth International Congress on Essential Fatty Acids and Eicosanoids : Invited Papers From the Fourth International Congress. Champaign, Ill: Amer Oil Chemists Society Press. , pp.303-311.
• Jiang, W. G. et al. 1998. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. British Journal of Cancer 77 (5), pp.731-738. (10.1038/bjc.1998.120)
• Jiang, W. G. et al. 1998. Essential fatty acids regulate the expression of tumour suppressor genes in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids Edinburgh, UK 20-24 July 1997. Published in: Riemersma, R. A. et al., Essential fatty acids and eicosanoids: invited papers from the Fourth International Congress. Champaign, Illinois: AOCS Press. , pp.303-311.
• Thomas, D. W. et al., 1998. Phenotypic variation in HGF production and bioactivity between oral and skin fibroblasts. Journal of Dental Research 77 (Supp 2), pp.767-767. (10.1177/0022034598077S201)

1997

• Jiang, W. G. and Hiscox, S. 1997. Quantification of tumour cell-endothelial cell attachment by 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI). Cancer Letters 112 (2), pp.209-217. (10.1016/S0304-3835(96)04573-9)
• Davies, E. et al. 1997. The role of desmoglein 2 and E-cadherin in the invasion and motility of human breast cancer cells. International Journal of Oncology 11 (2), pp.415-419.
• Hiscox, S. E. et al. 1997. Expression of the HGF/SF Receptor, c-met, and its ligand in human colorectal cancers. Cancer Investigation 15 (6), pp.513-521. (10.3109/07357909709047592)
• Hiscox, S. E. and Jiang, W. G. 1997. Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. Biochemical and Biophysical Research Communications 233 (1), pp.1-5. (10.1006/bbrc.1997.6388)
• Jiang, W. G. and Hiscox, S. 1997. Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Research 17 , pp.1349-1354.
• Jiang, W. G. and Hiscox, S. E. 1997. beta-catenin-cell adhesion and beyond (review). International Journal of Oncology 11 (3), pp.635-641.
• Jiang, W. G. and Hiscox, S. E. 1997. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histology and Histopathology 12 (2), pp.537-555.
• Jiang, W. G. et al. 1997. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochemical and Biophysical Research Communications 237 (3), pp.639-644. (10.1006/bbrc.1997.7154)
• Jiang, W. G. et al. 1997. Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Clinical and Experimental Metastasis 15 (6), pp.593-602. (10.1023/A:1018435229087)

1996

• Jiang, W. G. and Hiscox, S. E. 1996. Cytokine regulation of ezrin expression in the human colon cancer cell line HT29.. Anticancer Research 16 (2), pp.861-865.

1995

• Jiang, W. G. et al. 1995. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Research 55 , pp.5043-5048.